Source-grounded facts extracted from Krystal Biotech, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Krystal Biotech, Inc. reported first quarter ending March 31, 2026 results: revenue $116.4 million.
“Krystal Biotech Announces First Quarter 2026 Financial and Operating Results $116.4 million in 1Q VYJUVEK global revenue and $846.7 million since launch”
Krystal Biotech, Inc. reported the first quarter ending March 31, 2024 results: revenue $45.3 million.
“The Company recorded $45.3 million in VYJUVEK net product revenue for the first quarter of 2024.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.